Current Report Filing (8-k)
November 17 2014 - 4:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 17, 2014
Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
000-30929 |
|
13-4087132 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)
(212) 531-5965
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act. |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
A special meeting of stockholders
of Keryx Biopharmaceuticals, Inc. (Keryx or the Company) was held on November 17, 2014. Stockholders voted to approve an amendment to the Companys 2013 Incentive Plan to increase the number of authorized shares
issuable thereunder from 3,500,000 to 9,500,000 (the Amendment).
The vote with respect to the Amendment is set forth below:
|
|
|
|
|
Total Votes For |
|
Total Votes Against |
|
Abstentions |
51,155,027 |
|
3,953,134 |
|
128,153 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Keryx Biopharmaceuticals, Inc. |
|
|
|
|
(Registrant) |
|
|
|
|
Date: November 17, 2014 |
|
|
|
By: |
|
/s/ James F. Oliviero |
|
|
|
|
James F. Oliviero |
|
|
|
|
Chief Financial Officer |
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024